Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, N.I.H., Extramural

Research Support, Non-U.S. Gov't

Research Support, U.S. Gov't, Non-P.H.S.

Review

Case Reports

Clinical Trial, Phase I

Controlled Clinical Trial

Publication Year

From

Quick links

Individual year

2024

2022

2018

2016

2013

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Receptors, Enterotoxin""[mesh_terms]

7 Results

Searching titles within these results

GUCY2C: at the intersection of obesity and cancer.

Jieru E Lin, Scott A Waldman, Gilbert W Kim

Trends in endocrinology and metabolism: TEM 2013;24(4):165-73

Free Full Text

Abstract

T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.

John C Flickinger, Jagmohan Singh, Yanki Yarman, Robert D Carlson, Joshua R Barton, Scott A Waldman, Adam E Snook

Frontiers in immunology 2022;13():855759

Free Full Text

Abstract

Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant.

Ian Guo Yi Wong, Jesse Cramer, Darlene Horton, Donald Basel, Ru-Jeng Teng, Michael Muriello, Abdul Elkadri, William Scott

American journal of medical genetics. Part A 2024;194(4):e63489

Full Text

Abstract

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Leo C Katz, David S Weinberg, Nathan R Foster, Gary Della'Zanna, Ryan P McMurray, Walter K Kraft, Angela Pallotto, David M Kastenberg, Christopher H Henry, Stephanie M Moleski, Paul J Limburg, Scott A Waldman

Cancer biology & therapy 2022;22(10-12):544-553

Free Full Text

Abstract

Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.

Philip B Miner

Expert opinion on pharmacotherapy 2018;19(2):177-183

Full Text

Abstract

Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.

M Zielińska, A Jarmuż, M Storr, J Fichna

Neurogastroenterology and motility 2016;27(8):1057-68

Full Text

Abstract

Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease.

Tom H Karlsen, Torunn Fiskerstrand, Johannes R Hov, John Baines, Rune R Tronstad, Martin Kummen, Kristian Holm, Hilde L von Volkmann, Jarl A Anmarkrud, Marte L Høivik, Bjørn Moum, Odd H Gilja, Trygve Hausken

Inflammatory bowel diseases 2018;23(10):1752-1761

Full Text

Abstract

Results: 1 – 7 / 7

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Receptors, Enterotoxin""[mesh_terms]

GUCY2C: at the intersection of obesity and cancer.

T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.

Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant.

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.

Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.

Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease.

Results for
""Receptors, Enterotoxin""[mesh_terms]